0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
RSS Email Alerts
Please Wait... Processing your request... Please Wait.

Perspective | 
Anna Petroni
JAMA Intern Med. 2013;173(13):1173. doi:10.1001/jamainternmed.2013.6509.

Original Investigation |  FREE
Richard A. Hughes, FRCP; Judith Charlton, MSc; Radoslav Latinovic, BSc; et al.
Arch Intern Med. 2006;166(12):1301-1304. doi:10.1001/archinte.166.12.1301.

Review Article |  FREE
Steven L. Galetta, MD; Clyde Markowitz, MD; Andrew G. Lee, MD
Arch Intern Med. 2002;162(19):2161-2169. doi:10.1001/archinte.162.19.2161.

Sign in

Purchase Options

• Subscribe to the journal
• Rent this article ?

A free personal account provides

• Free current issues on The JAMA Network Reader
• Free quizzes on The JAMA Network Challenge
• Commenting and personalized alerts
From The JAMA Network
JAMA Neurology
Editorial  | 
Targeting the Interleukin 6 Receptor to Treat Neuromyelitis Optica
Sarosh R. Irani, MD, DPhil; Angela Vincent, FRCPath
JAMA Neurology
Original Investigation  | 
Long-term Therapy With Interleukin 6 Receptor Blockade in Highly Active Neuromyelitis Optica Spectrum Disorder
Marius Ringelstein, MD; Ilya Ayzenberg, MD; Jens Harmel, MD; et al.
JAMA Neurology
Viewpoint  | 
The Patient Protection and Affordable Care Act and Chronic Neurological Illnesses:  Benefits and Challenges
Gregory J. Esper, MD, MBA; Daniel Hartung, PharmD, MPH; Orly Avitzur, MD, MBA
JAMA Neurology
Viewpoint  | 
How Critical Is the Blood-Brain Barrier to the Development of Neurotherapeutics?
Carmen Kut, BS; Stuart A. Grossman, MD; Jaishri Blakeley, MD